Synthetic Design Lab emerges with $20M to advance next-generation ADCs

CAR-T Digest - August 2020

22 Apr 2025: Synthetic Design Lab emerges with $20M to advance next-generation ADCs

Synthetic Design Lab launched with $20 million in seed funding to develop next-generation antibody-drug conjugates (ADCs) using its proprietary SYNTHBODY platform
The SYNTHBODY platform aims to deliver over 10 times more targeted payload compared to current ADCs, with plans to enter clinical trials in 2026
Synthetic Design Lab is focused on improving the efficacy, safety, and versatility of ADCs by overcoming current limitations in target selection and delivery efficiency
The company combines advancements in protein engineering, synthetic biology, and AI to engineer innovative ADC constructs for broader cancer treatment applications